Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KIWLE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
uS20240091372A1 3H9-vc-MMAE
|
|||||
| Synonyms |
3H9-vc-MMAE
Click to Show/Hide
|
|||||
| Organization |
PHAROSGEN CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
3H9
|
Antibody Info | ||||
| Antigen Name |
Prion-like protein doppel (PRND)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vc-MMAE
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
29.65 Nm
|
|||
| Method Description |
A cell line expressing doppel, HCT116, was selected and cultured with increasing concentrations of ADC. After 72 hours, viability of each culture was assessed. ICso values were calculated by logistic non-linear regression and reported as nM.
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||